The operator of the Almaraz and Trillio nuclear power stations in Spain is collaborating with French nuclear company Framatome on the possible commercial production at the Trillo power plant of the radioisotope lutetium-177 (Lu-177), which is used in nuclear medicine for the treatment of tumours.
According to the Madrid-based nuclear industry group Foro Nuclear, the project is in the preliminary stage with tests being carried out to determine the feasibility of Lu-177 production at the single-unit Trillo, in Guadalajara province, central Spain.
Plant operator Almaraz-Trillo Nuclear Power Plants (CNAT) said the process began in 2022 when a series of modifications were made to the plant to be able to produce Lu-177.
Want to keep reading?
Register free and get full access to NucNet for 14 days. No card required.
- Daily news briefing on the global nuclear industry
- Weekly, monthly and topical newsletters
- 24/7 coverage during nuclear incidents and safety events
- Full searchable archive, 30,000+ articles since 1991
- SMR and AMR project database
- Analysis, Focus pieces and infographics
- NucNet Style Guide for nuclear reporters and communicators
After the trial, keep a free account for a newsletter and a complimentary Plus article every two weeks. Or see our subscription plans for individuals and organisations.
See subscription options
